This segment focuses on the research, development, production, and marketing of human and veterinary vaccines. Liaoning Cheng Da Biotechnology Co., Ltd., a key subsidiary, drives innovation in vaccine technology. The company conducts clinical trials to evaluate the immunogenicity and safety of its vaccines, including rabies vaccines. This division leverages advanced cell culture techniques and purification processes to manufacture high-quality vaccines. The therapeutic focus is on preventing infectious diseases through prophylactic vaccination. The company's rabies vaccine, for example, has been approved in China and is used in post-exposure prophylaxis. Future opportunities include expanding the vaccine portfolio and exploring new vaccine technologies.

This segment engages in the trading of various commodities, including textile and apparel, chemical products, coal, aquatic products, timber, and steel. The company manages a complex supply chain to facilitate the import and export of these goods. Research and development activities focus on optimizing logistics and supply chain management to improve efficiency and reduce costs. Technologies used include data analytics and supply chain management software. This segment supports various industries by providing essential raw materials and finished products. Future opportunities include expanding the range of traded commodities and leveraging e-commerce platforms to enhance trading activities.

This segment involves securities and fund activities, including investments in various financial instruments. The company actively manages its investment portfolio to generate returns and support its overall business strategy. Research and development activities focus on identifying promising investment opportunities and developing sophisticated investment strategies. Technologies used include financial modeling and risk management software. This segment contributes to the company's financial stability and growth. Future opportunities include expanding its investment portfolio and exploring new investment areas, such as private equity and venture capital.